CorrespondenceResearch LetterDosing Penalty of Erythropoiesis-Stimulating Agents After Switching From Originator to Biosimilar Preparations in Stable Hemodialysis Patients
Research Letter
Section snippets
Acknowledgements
Support: None.
Financial Disclosure: Two authors report receipt of consulting fees (RMinutolo: Roche and Menarini; LDN: AbbVie, Merck, and Bristol Myers Squibb). DR has received honoraria for lectures for AbbVie, Amgen, Janssen, Kerix, Genzyme, and Shire. The remaining authors declare that they have no relevant financial interests.
Contributions: Research idea/study design: RMinutolo, LDN, DR; data acquisition: MB, SS, CA, GC, CM, OF, DS, RMusacchio, PI, FF; data analysis/interpretation:
References (10)
- et al.
Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis
Am J Kidney Dis
(2013) - et al.
Control of rHuEPO biological activity: the role of carbohydrate
Exp Hematol
(2004) - et al.
Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis
Clin Nephrol
(2009) - et al.
Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia
Adv Ther
(2010) - et al.
Comparison of the therapeutic effects of epoetin zeta and epoetin alfa in the correction of renal anaemia
Curr Med Res Opin
(2008)
There are more references available in the full text version of this article.
© 2016 by the National Kidney Foundation, Inc.